Inhalation Sciences news roundup fall 2020
NEW PUBLICATION, NEW SALES, NEW JOINT DEVELOPMENT PROJECT: News roundup for Fall 2020 for Inhalation Sciences
ISAB & ASTRAZENECA: LANDMARK PAPER ON PRECISEINHALE® IN LARGE ANIMALS RELEASED
Inhalation Sciences and AstraZeneca have published results from a landmark study into the pharmacokinetics of inhaled substances administered by PreciseInhale® to pigs, whose respiratory tracts closely resemble that of humans. “This is of major significance as we move forward towards clinical validation of PreciseInhale®” says CEO Manoush Masarrat.
ISAB & UNIVERSITY OF VIENNA: NEW PRECISEINHALE ORDER WORTH 196 KEURO SIGNED
The Department of Pharmaceutical Technology and Biopharmaceutics at the University of Vienna carries out highly innovative research into new micro and nano formulations of pharmaceuticals. It has now ordered PreciseInhale®, ISAB’s high-precision aerosol R&D system, plus its Nose-Only and the unique Intratracheal Exposure Modules. The total order is worth 196 KEURO.
VITO, THE FLEMISH INSTITUTE FOR TECHNOLOGICAL RESEARCH ”WE WILL USE PRECISEINHALE® AS A VALUABLE TOOL FOR SAFETY & EFFICACY”
One of Europe’s most innovative research organisations, driving new technology worldwide in sustainable health, chemistry, energy and land use, is purchasing PreciseInhale[®], ISAB’s high-precision aerosol R&D system, together with its Particle Size Determination kit and Inhaler Aerosol Generator option for both DPI and /pMDI inhalers. The combined value of the order is 1.4 MSEK.
JOINT DEVELOPMENT PROJECT ON XPOSEALI® LONG-TERM PARTNER SIGNS DEAL WORTH 25 KEUR
A joint venture, to optimize and co-develop XposeALI®, ISAB’s in vitro aerosol exposure module of cells cultured at an Air-Liquid Interface (ALI), has been proposed to increase its compatibility with different types of commercial cell culture inserts. ISAB’s collaborating partner is a long-term client and all improvements made to XposeALI® during the project will remain proprietary to ISAB.
MEET ”IRS” INHALATION RESEARCH SERVICES – ISAB’S NEWLY REBRANDED CONTRACT RESEARCH ORGANIZATION
ISAB has repositioned its Contract Research business and launched it under a new brand name – Inhalation Research Services (IRS). IRS offers a comprehensive service portfolio that delivers precise and predictive early-stage respiratory research data. IRS has seen a steady increase in demand from its biopharma customers and has grown considerably during the Covid-19 pandemic.